Loading clinical trials...
Loading clinical trials...
Open-label, Non-randomized, Phase IIa Study to Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Adult Patients With Relapsed Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Conditions
Interventions
Antroquinonol
Locations
2
Russia
City Clinical Hospital n.a. S.P.Botkin
Moscow, Russia
Tula Regional Clinical Hospital
Tula, Russia
Start Date
February 20, 2019
Primary Completion Date
December 31, 2020
Completion Date
December 31, 2020
Last Updated
February 3, 2021
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06326268
Lead Sponsor
Golden Biotechnology Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions